Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPE K Rowinsky, L Smith, Y M Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemiaS D Gore, E K Rowinsky, C B Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesE K Rowinsky, T R Johnson, C E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group studyS O'Reilly, G F Fleming, S D Barker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignanciesM A Villalona-Calero, G R Weiss, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignanciesM A Villalona-Calero, J P Eder, D L Toppmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyW Zhang, T Winder, Y Ning, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPE K Rowinsky, L Smith, Y M Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemiaS D Gore, E K Rowinsky, C B Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesE K Rowinsky, T R Johnson, C E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group studyS O'Reilly, G F Fleming, S D Barker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignanciesM A Villalona-Calero, G R Weiss, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignanciesM A Villalona-Calero, J P Eder, D L Toppmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyW Zhang, T Winder, Y Ning, et al.
Pageof 16